UNASSIGNED: This single-center, retrospective, interventional, comparative study included eyes with visual impairment due to treatment-naive DME that underwent intravitreal injection of either aflibercept 2 mg/0.05 mL or ranibizumab 0.5 mg/0.05 mL at Al-Azhar University Hospitals, Egypt between March 2023 and January 2024. Demographic data and full ophthalmological examination results at baseline and 1, 3, and 6 months post-injection were collected, including the best-corrected distance visual acuity (BCDVA) in logarithm of the minimum angle of resolution (logMAR) notation, slit-lamp biomicroscopy, dilated fundoscopy, and central subfield thickness (CST) measured using spectral-domain optical coherence tomography.
UNASSIGNED: Overall, the 96 eyes of 96 patients with a median (interquartile range [IQR]) age of 57 (10) (range: 20-74) years and a male-to-female ratio of 1:2.7 were allocated to one of two groups with comparable age, sex, diabetes mellitus duration, and presence of other comorbidities (all P >0.05). There was no statistically significant difference in baseline diabetic retinopathy status or DME type between groups (both P >0.05). In both groups, the median (IQR) BCDVA significantly improved from 0.7 (0.8) logMAR at baseline to 0.4 (0.1) logMAR at 6 months post-injection (both P = 0.001), with no statistically significant difference between groups at all follow-up visits (all P >0.05). The median (IQR) CST significantly decreased in the aflibercept group from 347 (166) µm at baseline to 180 (233) µm at 6 months post-injection, and it decreased in the ranibizumab group from 360 (180) µm at baseline to 190 (224) µm at 6 months post-injection (both P = 0.001), with no statistically significant differences between groups at all follow-up visits (all P >0.05). No serious adverse effects were documented in either group.
UNASSIGNED: Ranibizumab and aflibercept were equally effective in achieving the desired anatomical and functional results in patients with treatment-naïve DME in short-term follow-up without significant differences in injection counts between both drugs. Larger prospective, randomized, double-blinded trials with longer follow-up periods are needed to confirm our preliminary results.
■这个单中心,回顾性,介入,对比研究纳入了在Al-Azhar大学医院玻璃体内注射阿柏西普2mg/0.05mL或雷珠单抗0.5mg/0.05mL的未治疗DME导致视力障碍的眼睛,2023年3月至2024年1月之间的埃及。收集基线和注射后1、3和6个月的人口统计学数据和完整的眼科检查结果,包括以最小分辨率角(logMAR)表示法的对数表示的最佳矫正远距视力(BCDVA),裂隙灯生物显微镜,扩张眼底镜检查,和使用谱域光学相干层析成像测量的中心子场厚度(CST)。
■总的来说,将96例中位(四分位距[IQR])年龄为57(10)(范围:20-74)岁,男女比例为1:2.7的患者的96只眼分配到两组中的一组,年龄相当,性别,糖尿病持续时间,并存在其他合并症(均P>0.05)。基线糖尿病视网膜病变状态或DME类型组间差异无统计学意义(均P>0.05)。在这两组中,中位数(IQR)BCDVA从基线时的0.7(0.8)logMAR显着改善至注射后6个月时的0.4(0.1)logMAR(均P=0.001),在所有随访中,组间差异无统计学意义(均P>0.05)。阿柏西普组的中位数(IQR)CST从基线时的347(166)µm显着降低至注射后6个月时的180(233)µm,雷珠单抗组从基线时的360(180)µm下降到注射后6个月时的190(224)µm(均P=0.001),在所有随访中,组间差异无统计学意义(均P>0.05)。两组均无严重不良反应记录。
雷珠单抗和阿柏西普在短期随访中对未治疗DME患者的解剖和功能结果同样有效,两种药物之间的注射计数没有显着差异。更大的前景,随机化,需要进行随访时间较长的双盲试验,以确认我们的初步结果.